

21 November 2019

## Results of 2019 Annual General Meeting

PYC Therapeutics Limited (**ASX:PYC**)(the **Company**) pursuant to ASX Listing Rule 3.12.2 advises that all resolutions contained in the Notice of Meeting dated 14 October 2019 and put to shareholders at the Company's 2019 Annual General Meeting today were all passed unanimously on a show of hands.

In accordance with Section 251AA(1) of the Corporations Act, set out below are the total number of proxies which were received in respect of each resolution.

RESOLUTION TITLE	FOR	AGAINST	OPEN	ABSTAIN / EXCLUDED
1. Remuneration Report	479,832,723	452,988	10,447,101	1,020,699,801
2. Election - Rohan Hockings	1,500,813,234	151,321	10,447,101	20,957
3. Election - Alan Tribe	1,500,924,555	40,000	10,447,101	20,957
4. 10% Placement Capacity	1,500,084,772	774,783	10,447,101	125,957
5. Change of Company Name	1,499,027,470	1,457,085	10,447,101	500,957

Yours faithfully

Kevin Hart

**Company Secretary**

**ENDS** For further information, please contact:

**INVESTORS**  
Rohan Hockings  
CEO  
info@pyctx.com

## About PYC Therapeutics

*PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

## Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**PYC Therapeutics Limited**

ACN 098 391 961